Press Release: HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture

regulatory agencies, which may affect the initiation, timing and progress of clinical trials or the regulatory pathway for the ATTC programs; and HUTCHMED's ability to successfully develop and commercialize the R&D programs. In addition, when or if used herein, the words and phrases "aims," "anticipates," "believes," "continue," "estimates," "expects," "intends," "may," "on track," "predicts," "plans, " "potential," "promising," "should," "to be," "will," and similar expressions and their variants, as they relate to HUTCHMED may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although HUTCHMED believes the expectations reflected in such forward-looking statements are reasonable, HUTCHMED can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied HUTCHMED's forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, assumptions regarding the safety, efficacy, supply, continued regulatory approval of these therapeutics, and in some cases connected to the risks of the use of other drug products as combination therapeutics. Forward-looking statements are neither historical facts nor assurances of future performance. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. For further discussion of these and other risks, see HUTCHMED's filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.

Inside Information

This announcement contains inside information for the purposes of Article 7 of Regulation $(EU)$ No 596/2014 (as it forms part of retained EU law as defined in the European Union (Withdrawal) Act 2018).

CONTACTS

 
Investor Enquiries                         +852 2121 8200 / ir@hutch-med.com 
 
Media Enquiries 
                                                  +44 20 3727 1030 / 
FTI Consulting --                             HUTCHMED@fticonsulting.com 
                                             +44 7771 913 902 (Mobile) / +44 
   Ben Atwell / Alex Shaw                         7779 545 055 (Mobile) 
                                               +852 9783 6894 (Mobile) / 
Brunswick -- Zhou Yi                          HUTCHMED@brunswickgroup.com 
 
Panmure Liberum                           Nominated Advisor and Joint Broker 
Atholl Tweedie / Freddy Crossley / 
 Rupert Dearden                                               +44 20 7886 2500 
 
HSBC                                                              Joint Broker 
Simon Alexander / Alina Vaskina / Arnav 
 Kapoor                                                       +44 20 7991 8888 
 
Cavendish                                                         Joint Broker 
Geoff Nash / Nigel Birks                                      +44 20 7220 0500 
 

(END) Dow Jones Newswires

January 01, 2025 05:46 ET (10:46 GMT)